Multiple Sclerosis Clinical Trial
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Summary
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S. Cardiometabolic risk factors including obesity and hyperlipidemia are common among people with MS, and these risk factors are associated with severity and frequency of MS relapses and disease progression. People with MS often experience symptoms of pain, fatigue, and depression, which make adhering to a healthy lifestyle difficult, as evidenced by the high rates of unhealthy behaviors including poor diet and physical inactivity among this group. Physical activity has reduced symptoms of MS and improved metabolic risk profiles, but little research has focused on the role of a dietary intervention combined with physical activity in this group. Therefore, the purpose of this study is to test the efficacy of a combined diet and physical activity intervention for reducing cardiometabolic risks and MS symptoms when compared to a physical activity intervention alone.
Eligibility Criteria
Inclusion Criteria:
Relapsing-Remitting MS
On disease modifying treatment for 6 months
No relapse within the previous 30 days
BMI 25-55 kg/m2
Self-identify as not currently meeting recommendations for healthy diet and physical activity
Ambulatory with or without assistance
Reliable access to the internet via computer or smartphone
Responsible for their personal food preparation or have input into the food prepared for them
Score indicating low cognitive functioning on the Telephone Interview for Cognitive Status assessment
Exclusion Criteria:
Physician does not approve participation
Use of the following diabetes medications: Acetohexamide, Chlorpropamide (Diabinese), Tolbutamide (Orinase, Tol-Tab), Tolazamide (Tolinase), Glipizide (Glucotrol, Glucotrol XL, Metaglip), Glyburide (Micronase, DiaBeta, Glynase, Glucovance), Glimepiride (Amaryl), Humalog or lispro, Novolog or aspart, Apidra or glulisine, Regular (R) humulin or novolin, Velosulin (for use in the insulin pump), NPH (N), Lente (L), Ultralente (U), Lantus, Levemir or detemir, Humulin 70/30, Novolin 70/30, Novolog 70/30, Humulin 50/50, or Humalog mix 75/25
Already on a specific diet meant to improve health
Heart attack, stroke, or heart bypass surgery less than 6 months ago
Pulmonary disease, cardiovascular disease or renal failure less than 6 months ago
Smoking
Cancer, HIV or liver/kidney disease
Inability to travel to Lakeshore for testing
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Birmingham Alabama, 35209, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.